Quick Guide:  Flaminal®, A versatile solution to reduce the risk of infection in acute and chronic wounds

Share this article

Quick Guide:  Flaminal®, A versatile solution to reduce the risk of infection in acute and chronic wounds

Supported by Flen Health
23 October 2023

Use of Flaminal® in practice 

Flaminal® is a primary wound dressing, categorised as an enzyme alginogel. Composed of a hydrated alginate matrix alongside its unique GLG — glucose oxidase combined with lactoperoxidase, stabilised by guaiacol antimicrobial enzyme system, it is safe to use on skin and wound tissue. Its various modes of action eliminate the need for multiple products. 

Antimicrobial activity of the GLG enzyme system 

Within the gel, Flaminal® contains an antimicrobial GLG enzymatic complex. These naturally occurring enzymes are found in milk and secretions of exocrine glands, such as saliva, tears and cervical mucus. 

They work by producing reactive oxygen radicals that destroy bacterial cell walls and fungal growth, similar to our innate white cell defences (White, 2006). Flaminal® acts only on bacteria that have been absorbed into the gel matrix and not within the wound bed, preserving essential skin and tissue without cytotoxicity. It also reduces biofilm-released bacteria, protecting wounds from infection (Cooper, 2013). 

To date, no instances of antimicrobial resistance (AMR) have been recorded with Flaminal® (Gottrup et al, 2013; Flen Health internal data on file, 2021).

Antimicrobial stewardship (AMS) 

Widespread, inappropriate antimicrobial use to treat both acute and chronic wounds with spreading and systemic infections has contributed to the rise of AMR. If no action is taken, it is estimated that antimicrobial drug-resistant diseases could cause 10 million deaths each year by 2050 (Interagency Coordinating Group on Antimicrobial Resistance, 2019). 

Antimicrobial stewardship (AMS) is an approach that aims to reduce the risk of AMR through education and public awareness. It encourages clinicians to use antimicrobial treatment at the appropriate dose and duration, only when necessary, thereby avoiding unnecessary use in non-infected wounds. 

The development of innovative antimicrobial wound care alternatives with minimal cytotoxicity and adverse risks, such as Flaminal®, is a key aspect of AMS and important to achieve the best clinical outcomes for patients. 

Download the full resource below.

Disclaimer: Supported by Flen Health

Cooper RA (2013) Int Wound J 10(6): 630–7

De Smet K, van des Plas D, Lens D, Sollie P (2009) Wounds 21(3): 65-73

Flen Health (2021) Long-term efficacy of GLG antimicrobial properties. Internal data on file

Gottrup F, Apelqvist J, Bjarnsholt T et al (2013) J Wound Care 22 (5): S1-S92

Interagency Coordinating Group on Antimicrobial Resistance (2019) Report to the Secretary-General of the United Nations

International Wound Infection Institute (2022) Wounds International

White R (2006) Wounds UK 2: 64 –9

Wounds UK (2020) Wounds UK

Free for all healthcare professionals

Sign up to the Wounds Group journals

By clicking ‘Subscribe’, you are agreeing that the Wounds Group are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our privacy policy.

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.

I am not a healthcare professional.